All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
During the European Hematology Association (EHA) 2023 Hybrid Congress, the GvHD Hub was pleased to speak with Yanmin Zhao, Zhejiang University, Hangzhou, CN. We asked, Is the novel JAK/ROCK inhibitor TQ05105 effective for patients with steroid refractory and steroid dependent chronic graft-versus-host disease?
Is the novel JAK/ROCK inhibitor TQ05105 effective for patients with SR/SD cGvHD?
Zhao begins by providing a brief overview of the phase Ib/II trial of TQ05105 in patients with steroid refractory or steroid dependent chronic graft-versus-host disease (NCT04944043). With a best overall response rate of around 87% and a 6-month overall response rate of nearly 60%, she believes that TQ05105 may provide a new treatment option for these patients.
Expert Opinion from our Chair, Mohamad Mohty, on COVID-19 and GvHD
This transcript is provided from a call held between the GvHD/Multiple Myeloma Hub and Professor (Prof.) Mohamad Mohty. We would like to thank Prof. Mohty for taking the time to speak...
Investigating the feasibility of induced pluripotent stem cell (iPSC) banking and transplantation in allogeneic settings
Yasuo Morishima and colleagues, Aichi Cancer Center Research Institute, Nagoya, JP, analyzed 5,017 single cord blood...
Subscribe to get the best content related to GvHD delivered to your inbox